Trial Profile

A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alunacedase alfa (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

15 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
27 Feb 2020 New trial record
26 Feb 2020 According to an Apeiron Biologics media release, data from this trial will be assessed to ascertain whether a Phase 2B clinical trial in a larger number of patients is warranted.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com